HIKMA PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,930 GBX | +0.89% |
|
-1.43% | +7.88% |
| May. 28 | Egypt, UAE talks continuing over Ras El Hekma land deal | RE |
| May. 17 | HIKMA PHARMACEUTICALS : Time to capitalise on Hikma’s ongoing (share price) momentum |  |
Financials (USD)
| Sales 2024 * | 2.99B | Sales 2025 * | 3.09B | Capitalization | 5.45B |
|---|---|---|---|---|---|
| Net income 2024 * | 414M | Net income 2025 * | 451M | EV / Sales 2024 * | 2.11 x |
| Net Debt 2024 * | 852M | Net Debt 2025 * | 607M | EV / Sales 2025 * | 1.96 x |
| P/E ratio 2024 * |
13.4
x | P/E ratio 2025 * |
12.3
x | Employees | 9,100 |
| Yield 2024 * |
2.9% | Yield 2025 * |
3.07% | Free-Float | 65.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hikma Pharmaceuticals PLC
More recommendations
More press releases
More news
| 1 day | +0.89% | ||
| 1 week | -1.43% | ||
| 1 month | +0.31% | ||
| 3 months | -1.88% | ||
| 6 months | +11.98% | ||
| Current year | +7.88% |
1 week
1 857.00
1 981.00
1 month
1 857.002 036.00
Current year
1 750.002 165.00
1 year
1 711.002 222.00
3 years
1 174.502 703.00
5 years
1 174.502 768.00
10 years
814.202 768.00
| Managers | Title | Age | Since |
|---|---|---|---|
Riad Mishlawi
CEO | Chief Executive Officer | 60 | 89-12-31 |
Khalid Nabilsi
DFI | Director of Finance/CFO | 52 | 00-12-31 |
Said Darwazah
CHM | Chairman | 67 | 80-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Douglas Hurt
BRD | Director/Board Member | 67 | 20-04-30 |
Nina Henderson
BRD | Director/Board Member | 72 | 16-09-30 |
Victoria Hull
BRD | Director/Board Member | 62 | 22-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.44% | 1,083 M€ | +4.80% | ||
| 0.25% | 3 M€ | +9.95% | - | |
| 0.20% | 11 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,930 | +0.89% | 1,597,912 |
| 24-05-30 | 1,913 | +0.31% | 325,327 |
| 24-05-29 | 1,907 | +0.10% | 442,777 |
| 24-05-28 | 1,905 | -2.71% | 253,041 |
| 24-05-24 | 1,958 | -0.05% | 159,271 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotes
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:
- generic injectable products (45.3%);
- brand name drugs (27.5%);
- generic products taken orally (26.7%);
- other (0.5%).
Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
24.56
USD
Average target price
28.68
USD
Spread / Average Target
+16.78%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.88% | 5.45B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- HIK Stock
